<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04484337</url>
  </required_header>
  <id_info>
    <org_study_id>212482</org_study_id>
    <nct_id>NCT04484337</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Pharmacokinetic (PK), Safety and Tolerability of Cabotegravir (CAB) 400 Milligrams Per Milliliter (mg/mL) Formulation in Healthy Adult Participants</brief_title>
  <official_title>A Phase 1, Two-part, Double-blind, Active-control, Randomized Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Repeat-Dose Cabotegravir (CAB 400 mg/mL Formulation) Long-Acting Injection Following Subcutaneous or Intramuscular Administration in Healthy Adult Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ViiV Healthcare</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ViiV Healthcare</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an active control, randomized study to investigate the safety, tolerability and PK of&#xD;
      repeat dose administration of long-acting CAB 400 mg/mL formulation intramuscular (IM)&#xD;
      (gluteus medius and vastus lateralis) and subcutaneous (SC) (abdominal) injections in healthy&#xD;
      adult participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 31, 2020</start_date>
  <completion_date type="Anticipated">February 24, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 24, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Participants will receive repeat doses of long-acting CAB 400 mg/mL or CAB 200 mg/mL at four-weekly (Q4W) interval in Part 1 and at 12-weekly (Q12W) interval in Part 2.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>This will be a double-blind (sponsor-unblind) study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed Plasma concentration (Cmax) for cabotegravir (Part 1 Injection 1)</measure>
    <time_frame>Injection 1 Day 1 to Injection 1 Week 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax for cabotegravir (Part 1 Injection 2)</measure>
    <time_frame>Injection 2 Day 1 to Week 52 follow-up</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax for cabotegravir (Part 2 Injection 1)</measure>
    <time_frame>Injection 1 Day 1 to Injection 1 Week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax for cabotegravir (Part 2 Injection 2)</measure>
    <time_frame>Injection 2 Day 1 to Week 52 follow-up</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time of maximum observed plasma concentration (Tmax) for cabotegravir (Part 1 Injection 1)</measure>
    <time_frame>Injection 1 Day 1 to Injection 1 Week 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax for cabotegravir (Part 1 Injection 2)</measure>
    <time_frame>Injection 2 Day 1 to Week 52 follow-up</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax for cabotegravir (Part 2 Injection 1)</measure>
    <time_frame>Injection 1 Day 1 to Injection 1 Week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax for cabotegravir (Part 2 Injection 2)</measure>
    <time_frame>Injection 2 Day 1 to Week 52 follow-up</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration - time curve from time zero to last quantifiable time point (AUC[0-t]) for cabotegravir (Part 1 Injection 1)</measure>
    <time_frame>Injection 1 Day 1 to Injection 1 Week 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-t) for cabotegravir (Part 1 Injection 2)</measure>
    <time_frame>Injection 2 Day 1 to Injection 2 Week 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-t) for cabotegravir (Part 2 Injection 1)</measure>
    <time_frame>Injection 1 Day 1 to Injection 1 Week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC(0-t) for cabotegravir (Part 2 Injection 2)</measure>
    <time_frame>Injection 2 Day 1 to Injection 2 Week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Trough concentrations (Ctau) for cabotegravir (Part 1 Injection 1)</measure>
    <time_frame>Injection 1 Day 1 to Injection 1 Week 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Ctau for cabotegravir (Part 1 Injection 2)</measure>
    <time_frame>Injection 2 Day 1 to Injection 2 Week 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Ctau for cabotegravir (Part 2 Injection 1)</measure>
    <time_frame>Injection 1 Day 1 to Injection 1 Week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Ctau for cabotegravir (Part 2 Injection 2)</measure>
    <time_frame>Injection 2 Day 1 to Injection 2 Week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent terminal phase half-life (T1/2) for cabotegravir (Part 1 Injection 2)</measure>
    <time_frame>Injection 2 Week 4 to Week 52 follow-up</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>T1/2 for cabotegravir (Part 2 Injection 2)</measure>
    <time_frame>Injection 2 Week 12 to Week 52 follow-up</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Absorption rate constant (KALA) for cabotegravir (Part 1 Injection 2)</measure>
    <time_frame>Injection 2 Week 4 to Week 52 follow-up</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>KALA for cabotegravir (Part 2 Injection 2)</measure>
    <time_frame>Injection 2 Week 12 to Week 52 follow-up</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric mean ratio of plasma Ctau of CAB for Cohorts 1,2,3,4 at Week 4 (Part 1 Injection 1) compared to historical data of CAB 200 mg/mL IM (gluteus medius) (Week 8 Ctau following first injection at Week 4b in ATLAS [Study 201585]/FLAIR [Study 201584])</measure>
    <time_frame>At Injection 1 Week 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric mean ratio of plasma Ctau of CAB for Cohorts 1,2,3,4 at Week 4 (Part 1 Injection 2) compared to historical data of CAB 200 mg/mL IM (gluteus medius) (Week 12 Ctau following first injection at Week 8 in ATLAS [Study 201585]/FLAIR [Study 201584])</measure>
    <time_frame>At Injection 2 Week 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric mean ratio of plasma Ctau of CAB for Cohorts 5 and 6 at Week 12(Part 2 Injection 1) compared to historical data of CAB 200 mg/mL IM (gluteus medius) (Week 8 Ctau following first injection at Week 4b in ATLAS [Study 201585]/FLAIR [Study 201584])</measure>
    <time_frame>At Injection 1 Week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric mean ratio of plasma trough concentration (Ctau) of cabotegravir at Week 4 (Part 1 Injection 1) for each pairwise comparison between Cohorts 1, 2, 3 and 4</measure>
    <time_frame>At Injection 1 Week 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric mean ratio of plasma trough concentration (Ctau) of cabotegravir at Week 4 (Part 1 Injection 2) for each pairwise comparison between Cohorts 1, 2, 3 and 4</measure>
    <time_frame>At Injection 2 Week 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric mean ratio of Plasma AUC(0-t) of cabotegravir at Week 4 (Part 1 Injection 1) for each pairwise comparison between Cohorts 1, 2, 3 and 4</measure>
    <time_frame>At Injection 1 Week 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric mean ratio of Plasma Cmax of cabotegravir at Week 4 (Part 1 Injection 2) for each pairwise comparison between Cohorts 1, 2, 3 and 4</measure>
    <time_frame>At Injection 2 Week 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric mean ratio of Plasma Cmax of cabotegravir at Week 4 (Part 1 Injection 1) for each pairwise comparison between Cohorts 1, 2, 3 and 4</measure>
    <time_frame>At Injection 1 Week 4</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Geometric mean ratio of Plasma AUC(0-t) of cabotegravir at Week 4 (Part 1 Injection 2) for each pairwise comparison between Cohorts 1, 2, 3 and 4</measure>
    <time_frame>At Injection 2 Week 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Parts 1 and 2: Number of participants with adverse events (AEs)</measure>
    <time_frame>Up to 52 weeks follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with liver biochemistry abnormalities</measure>
    <time_frame>Up to 52 weeks follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax for cabotegravir following oral 30 mg administration</measure>
    <time_frame>Up to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tmax for cabotegravir following oral 30 mg administration</measure>
    <time_frame>Up to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-t) for cabotegravir following oral 30 mg administration</measure>
    <time_frame>Up to Day 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration at 24 hours (C24) for cabotegravir following oral 30 mg administration</measure>
    <time_frame>At 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ctau for cabotegravir at Day 29 following oral 30 mg administration</measure>
    <time_frame>Up to Day 29</time_frame>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Anticipated">124</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Part 1:Cohort 1: CAB 400 mg/mL IM gluteal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible participants will receive 1 tablet of CAB 30 mg once daily for 28 days during the oral lead-in phase, followed by a wash out period of 7 to 14 days. On Day 1 of Part 1, participants will be administered a loading dose of CAB 600 mg given as 1 x 1.5 mL CAB 400 mg/mL formulation via IM gluteal injection. Participants will receive a second injection of CAB 400 mg given as 1 x 1 mL CAB 400 mg/mL via IM gluteal injection at Week 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1:Cohort 1: CAB 200 mg/mL IM gluteal</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eligible participants will receive 1 tablet of CAB 30 mg once daily for 28 days during the oral lead-in phase, followed by a wash out period of 7 to 14 days. On Day 1 of Part 1, participants will be administered a loading dose of CAB 600 mg given as 1 x 3 mL CAB 200 mg/mL via IM gluteal injection. Participants will receive a second injection of CAB 400 mg given as 1 x 2 mL CAB 200 mg/mL via IM gluteal injection at Week 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1:Cohort 2: CAB 400 mg/mL SC abdominal</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible participants will receive 1 tablet of CAB 30 mg once daily for 28 days during the oral lead-in phase, followed by a wash out period of 7 to 14 days. On Day 1 of Part 1, participants will be administered a loading dose of CAB 600 mg given as 1 x 1.5 mL CAB 400 mg/mL formulation via SC abdominal injection. Participants will receive a second injection of CAB 200 mg given as 1 x 0.5 mL CAB 400 mg/mL via SC abdominal at Week 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1:Cohort 2: CAB 200 mg/mL SC abdominal</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eligible participants will receive 1 tablet of CAB 30 mg once daily for 28 days during the oral lead-in phase, followed by a wash out period of 7 to 14 days. On Day 1 of Part 1, participants will be administered a loading dose of CAB 300 mg as 1x 1.5 mL CAB 200 mg/mL via SC abdominal injection. Participants will receive a second injection of CAB 100 mg as 1 x 0.5 mL CAB 200 mg/mL SC abdominal at Week 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1:Cohort 3: CAB 400 mg/mL IM (lateral thigh)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible participants will receive 1 tablet of CAB 30 mg once daily for 28 days during the oral lead-in phase, followed by a wash out period of 7 to 14 days. On Day 1 of Part 1, participants will be administered a loading dose of CAB 600 mg given as 1 x 1.5 mL or 400 mg given as 1 x 1 mL CAB 400 mg/mL formulation via IM (lateral thigh) injection. Participants will receive a second injection of CAB 400 mg given as 1 x 1 mL CAB 400 mg/mL via IM (lateral thigh) at Week 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1:Cohort 3: CAB 200 mg/mL IM (lateral thigh)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eligible participants will receive 1 tablet of CAB 30 mg once daily for 28 days during the oral lead-in phase, followed by a wash out period of 7 to 14 days. On Day 1 of Part 1, participants will be administered a loading dose of 600 mg given as 1 x 3 mL or 400 mg as 1 x 2 mL CAB 200 mg/mL via IM (lateral thigh) injection. Participants will receive a second injection of 400 mg as 1 x 2 mL CAB 200 mg/mL via IM (lateral thigh) at Week 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Cohort 4: CAB 400 mg/mL (IM or SC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible participants will receive 1 tablet of CAB 30 mg once daily for 28 days during the oral lead-in phase, followed by a wash out period of 7 to 14 days. On Day 1 of Part 1, participants will be administered a loading dose of 400 mg as 1 x 1 mL CAB 400 mg/mL via IM (gluteal injection). Participants will receive a second injection of 200 mg as 1 x 0.5 mL CAB 400 mg/mL via SC (abdominal) at Week 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Cohort 4: CAB 200 mg/mL (IM or SC)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eligible participants will receive 1 tablet of CAB 30 mg once daily for 28 days during the oral lead-in phase, followed by a wash out period of 7 to 14 days. On Day 1 of Part 1, participants will be administered a loading dose of 400 mg as 1 x 2 mL CAB 200 mg/mL via IM (gluteal injection). Participants will receive a second injection of 100 mg as 1 x 0.5 mL CAB 200 mg/mL via SC (abdominal) at Week 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Cohort 5: CAB 400 mg/mL IM (gluteus medius)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible participants will receive 1 tablet of CAB 30 mg once daily for 28 days during the oral lead-in phase, followed by a wash out period of 7 to 14 days. On Day 1 of Part 1, participants will be administered a loading dose of 800 mg as 1 x 2 mL CAB 400 mg/mL via IM (gluteus medius) injection. Participants will receive a second injection of CAB 400 mg/mL formulation via IM (gluteal injection) 12 weeks apart. The determination of the dose of the second injection will be governed by the Study Team safety and PK Review (STR).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Cohort 5: CAB 200 mg/mL IM (gluteus medius)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eligible participants will receive 1 tablet of CAB 30 mg once daily for 28 days during the oral lead-in phase, followed by a wash out period of 7 to 14 days. On Day 1 of Part 1, participants will be administered a loading dose of 400 mg as 1 x 2 mL CAB 200 mg/mL via IM (gluteus medius) injection. Participants will receive a second injection of CAB 200 mg/mL formulation via IM (gluteal injection) 12 weeks apart. The determination of the dose of the second injection will be governed by the STR.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Cohort 6: CAB 400 mg/mL IM (gluteus medius)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible participants will receive 1 tablet of CAB 30 mg once daily for 28 days during the oral lead-in phase, followed by a wash out period of 7 to 14 days. Participants will then receive two IM gluteal injections of CAB 400 mg/mL formulation administered 12 weeks apart. The determination of the dose and dosing schedule will be governed by the STR.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Cohort 6: CAB 200 mg/mL IM (gluteus medius)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Eligible participants will receive 1 tablet of CAB 30 mg once daily for 28 days during the oral lead-in phase, followed by a wash out period of 7 to 14 days. Participants will then receive two IM gluteal injections of CAB 200 mg/mL formulation administered 12 weeks apart. The determination of the dose and dosing schedule will be governed by the STR.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cabotegravir sodium (Oral Lead In)</intervention_name>
    <description>CAB will be available as 30 mg tablets for oral administration.</description>
    <arm_group_label>Part 1: Cohort 4: CAB 200 mg/mL (IM or SC)</arm_group_label>
    <arm_group_label>Part 1: Cohort 4: CAB 400 mg/mL (IM or SC)</arm_group_label>
    <arm_group_label>Part 1:Cohort 1: CAB 200 mg/mL IM gluteal</arm_group_label>
    <arm_group_label>Part 1:Cohort 1: CAB 400 mg/mL IM gluteal</arm_group_label>
    <arm_group_label>Part 1:Cohort 2: CAB 200 mg/mL SC abdominal</arm_group_label>
    <arm_group_label>Part 1:Cohort 2: CAB 400 mg/mL SC abdominal</arm_group_label>
    <arm_group_label>Part 1:Cohort 3: CAB 200 mg/mL IM (lateral thigh)</arm_group_label>
    <arm_group_label>Part 1:Cohort 3: CAB 400 mg/mL IM (lateral thigh)</arm_group_label>
    <arm_group_label>Part 2: Cohort 5: CAB 200 mg/mL IM (gluteus medius)</arm_group_label>
    <arm_group_label>Part 2: Cohort 5: CAB 400 mg/mL IM (gluteus medius)</arm_group_label>
    <arm_group_label>Part 2: Cohort 6: CAB 200 mg/mL IM (gluteus medius)</arm_group_label>
    <arm_group_label>Part 2: Cohort 6: CAB 400 mg/mL IM (gluteus medius)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cabotegravir 400 mg/mL</intervention_name>
    <description>CAB 400 mg/mL will be available for administration by IM injection or SC Injection.</description>
    <arm_group_label>Part 1: Cohort 4: CAB 400 mg/mL (IM or SC)</arm_group_label>
    <arm_group_label>Part 1:Cohort 1: CAB 400 mg/mL IM gluteal</arm_group_label>
    <arm_group_label>Part 1:Cohort 2: CAB 400 mg/mL SC abdominal</arm_group_label>
    <arm_group_label>Part 1:Cohort 3: CAB 400 mg/mL IM (lateral thigh)</arm_group_label>
    <arm_group_label>Part 2: Cohort 5: CAB 400 mg/mL IM (gluteus medius)</arm_group_label>
    <arm_group_label>Part 2: Cohort 6: CAB 400 mg/mL IM (gluteus medius)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cabotegravir 200 mg/mL</intervention_name>
    <description>CAB 200 mg/mL will be available for administration by IM injection or SC Injection.</description>
    <arm_group_label>Part 1: Cohort 4: CAB 200 mg/mL (IM or SC)</arm_group_label>
    <arm_group_label>Part 1:Cohort 1: CAB 200 mg/mL IM gluteal</arm_group_label>
    <arm_group_label>Part 1:Cohort 2: CAB 200 mg/mL SC abdominal</arm_group_label>
    <arm_group_label>Part 1:Cohort 3: CAB 200 mg/mL IM (lateral thigh)</arm_group_label>
    <arm_group_label>Part 2: Cohort 5: CAB 200 mg/mL IM (gluteus medius)</arm_group_label>
    <arm_group_label>Part 2: Cohort 6: CAB 200 mg/mL IM (gluteus medius)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participant must be 18 to 50 years of age inclusive, at the time of signing the&#xD;
             informed consent.&#xD;
&#xD;
          -  Participants who are overtly healthy as determined by medical evaluation.&#xD;
&#xD;
          -  A participant with a clinical abnormality or laboratory parameters which is/are not&#xD;
             specifically listed in the inclusion or exclusion criteria, outside the reference&#xD;
             range for the population being studied may be included if the investigator determines&#xD;
             and documents that the finding is unlikely to introduce additional risk factors and&#xD;
             will not interfere with the study procedures.&#xD;
&#xD;
          -  Participants who are negative on two consecutive tests for Severe acute respiratory&#xD;
             syndrome coronavirus 2 (SARS-CoV-2), performed at Screening and within 5 days of&#xD;
             admission to the Phase I unit, using an approved molecular test (Polymerase chain&#xD;
             reaction [PCR]).&#xD;
&#xD;
          -  Body weight more than or equal to (&gt;=)40 kilogram (kg) and body mass index (BMI)&#xD;
             within the range 18 to 32 kilogram per square meter (kg/m^2).&#xD;
&#xD;
          -  Male participants are eligible to participate if they agree to use contraceptive&#xD;
             methods and refrain from donating sperm.&#xD;
&#xD;
          -  A female participant is eligible to participate if she is not pregnant or&#xD;
             breastfeeding, and at least one of the following conditions applies: Is not a woman of&#xD;
             childbearing potential (WOCBP) or is a WOCBP and using a contraceptive method that is&#xD;
             highly effective, with a failure rate of less than (&lt;)1 percent(%).&#xD;
&#xD;
          -  Capable of giving signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Signs and symptoms which in the opinion of the investigator are suggestive of&#xD;
             Coronavirus disease 2019 (COVID-19) (that is [i.e.] fever, cough etc) within 14 days&#xD;
             of inpatient admission.&#xD;
&#xD;
          -  Contact with known COVID-19 positive person/s in the 14 days prior to inpatient&#xD;
             admission.&#xD;
&#xD;
          -  History or presence of/significant history of or current cardiovascular, respiratory,&#xD;
             hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders&#xD;
             capable of significantly altering the absorption, metabolism, or elimination of drugs;&#xD;
             constituting a risk when taking the study intervention or interfering with the&#xD;
             interpretation of data.&#xD;
&#xD;
          -  Abnormal blood pressure as determined by the investigator.&#xD;
&#xD;
          -  Alanine transaminase (ALT) more than (&gt;)1.5 times upper limit of normal (ULN).&#xD;
&#xD;
          -  Bilirubin &gt;1.5 times ULN (isolated bilirubin &gt;1.5 times ULN is acceptable if bilirubin&#xD;
             is fractionated and direct bilirubin &lt;35%).&#xD;
&#xD;
          -  Current or chronic history of liver disease, or known hepatic or biliary abnormalities&#xD;
             (with the exception of Gilbert's syndrome or asymptomatic gallstones).&#xD;
&#xD;
          -  Corrected QT interval (QTc) &gt;450 milliseconds (msec).&#xD;
&#xD;
          -  The participant has an underlying skin disease or disorder (infection, inflammation,&#xD;
             dermatitis, eczema, drug rash, drug allergy, psoriasis, food allergy, urticaria) that&#xD;
             would interfere with assessment of injection sites.&#xD;
&#xD;
          -  Current or anticipated need for chronic anti-coagulation with the exception of the use&#xD;
             of low dose acetylsalicylic acid (less than or equal to [&lt;=]325 mg) or hereditary&#xD;
             coagulation and platelet disorders such as hemophilia or Von Willebrand Disease.&#xD;
&#xD;
          -  Participants considered to have insufficient musculature to allow safe administration&#xD;
             of CAB 400 mg/mL (gluteus medius or vastus lateralis).&#xD;
&#xD;
          -  History of ongoing or clinically relevant seizure disorder within the previous 2&#xD;
             years, including participants who have required treatment for seizures within this&#xD;
             time period.&#xD;
&#xD;
          -  History of or on-going high-risk behaviors that may put the participant at increased&#xD;
             risk for Human Immunodeficiency Virus (HIV) acquisition in the opinion of the&#xD;
             investigator. This includes participants in HIV discordant relationships, or men who&#xD;
             report current or prior unprotected anal sex with other men and those reporting prior&#xD;
             or current injecting drug use.&#xD;
&#xD;
          -  Participation in another concurrent clinical study or prior clinical study (with the&#xD;
             exception of imaging trials) prior to the first dosing day in the current study: 30&#xD;
             days, 5 half-lives or twice the duration of the biological effect of the&#xD;
             investigational product (whichever is longer).&#xD;
&#xD;
          -  Participation in the study would result in loss of blood or blood products in excess&#xD;
             of 500 mL within 56 days.&#xD;
&#xD;
          -  The participant has participated in a clinical trial and has received an&#xD;
             investigational product within the following time period prior to the first dosing day&#xD;
             in the current study: 30 days, 5 half-lives or twice the duration of the biological&#xD;
             effect of the investigational product (whichever is longer).&#xD;
&#xD;
          -  Exposure to more than four new chemical entities within 12 months prior to the first&#xD;
             dosing day.&#xD;
&#xD;
          -  Presence of hepatitis B surface antigen (HBsAg), or positive hepatitis C antibody test&#xD;
             result at screening or within 3 months prior to first dose of study treatment.&#xD;
&#xD;
          -  A positive pre-study drug/alcohol screen.&#xD;
&#xD;
          -  Exclusion criteria for screening electrocardiogram (ECG):&#xD;
&#xD;
               1. Heart rate: For Males &lt;45 or &gt;100 beats per minute (bpm), for females &lt;50 or &gt;100&#xD;
                  bpm.&#xD;
&#xD;
               2. PR Interval: For males and females &lt;120 or &gt;220 msec.&#xD;
&#xD;
               3. QRS duration: For males and females &lt;70 or &gt;120 msec.&#xD;
&#xD;
               4. QT duration corrected for heart rate by Fridericia's formula (QTcF) interval: For&#xD;
                  males and females &gt;450 msec.&#xD;
&#xD;
          -  Evidence of previous myocardial infarction.&#xD;
&#xD;
          -  Any conduction abnormality (including but not specific to left or right complete&#xD;
             bundle branch block, atrioventricular [AV] block [2nd degree or higher],&#xD;
             Wolff-Parkinson-White [WPW] syndrome).&#xD;
&#xD;
          -  Sinus Pauses &gt;3 seconds.&#xD;
&#xD;
          -  Any significant arrhythmia which, in the opinion of the Investigator or&#xD;
             GlaxoSmithKline (GSK)/ViiV Medical monitor, will interfere with the safety for the&#xD;
             individual participant.&#xD;
&#xD;
          -  Non-sustained or sustained ventricular tachycardia (&gt;=3 consecutive ventricular&#xD;
             ectopic beats).&#xD;
&#xD;
          -  Positive HIV antibody/antigen test. Participants will be advised regarding safer sex.&#xD;
             In the event a participant acquires HIV during the course of the study they will be&#xD;
             required to withdraw from the study and will be referred urgently to an HIV treatment&#xD;
             center for further management.&#xD;
&#xD;
          -  Regular use of known drugs of abuse.&#xD;
&#xD;
          -  Regular use of tobacco- or nicotine-containing products within 3 months prior to&#xD;
             screening.&#xD;
&#xD;
          -  History of sensitivity to any of the study medications, or components thereof or a&#xD;
             history of drug or other allergy.&#xD;
&#xD;
          -  Regular alcohol consumption within 6 months prior to the study defined as: An average&#xD;
             weekly intake of &gt;14 units for males or &gt;7 units for females.&#xD;
&#xD;
          -  Urinary cotinine levels indicative of smoking or history or regular use of tobacco- or&#xD;
             nicotine-containing products (e.g. nicotine patches or vaporizing devices) within 6&#xD;
             months prior to screening.&#xD;
&#xD;
          -  The participant has a tattoo or other dermatological condition overlying the location&#xD;
             of injection or a prior history of silicone implants (gluteal) which may interfere&#xD;
             with interpretation of injection site reactions or administration of CAB LA.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>ViiV Healthcare</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US GSK Clinical Trials Call Center</last_name>
    <phone>877-379-3718</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>EU GSK Clinical Trials Call Center</last_name>
    <phone>+44 (0) 20 89904466</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>James Dale Taylor II</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Darin Brimhall</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <state>New Jersey</state>
        <zip>08009</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Michael A Hassman</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Rebecca Wood-Horrall</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Auckland</city>
        <zip>1010</zip>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Christian Schwabe</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>New Zealand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 20, 2020</study_first_submitted>
  <study_first_submitted_qc>July 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2020</study_first_posted>
  <last_update_submitted>July 6, 2021</last_update_submitted>
  <last_update_submitted_qc>July 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cabotegravir</keyword>
  <keyword>Long-Acting Injection</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Safety</keyword>
  <keyword>Tolerability</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cabotegravir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD for this study will be made available via the Clinical Study Data Request site.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.</ipd_time_frame>
    <ipd_access_criteria>Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.</ipd_access_criteria>
    <ipd_url>http://clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

